NCT06282874 2026-04-09
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Active not recruiting
Guangdong Association of Clinical Trials
NYU Langone Health
City of Hope Medical Center
University of Zurich
Guangzhou Medical University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Plus Therapeutics